Delcath Systems, Inc. reported total revenue of $15.1 million for the fourth quarter ended December 31, 2024, a significant increase from $0.5 million in the same period of the prior year. U.S. sales of HEPZATO KIT contributed $13.7 million, while CHEMOSAT sales in Europe accounted for $1.4 million.
For the full year 2024, total revenue reached $37.2 million, compared to $2.1 million in 2023, with U.S. HEPZATO sales at $32.3 million and European CHEMOSAT sales at $4.9 million. The company reported a net loss of $3.4 million for Q4 2024 and $26.4 million for the full year 2024, showing improvement from prior year losses.
Crucially, Delcath achieved a positive non-GAAP adjusted EBITDA of $4.6 million for the fourth quarter of 2024, a notable improvement from a loss of $9.3 million in Q4 2023. As of December 31, 2024, the company maintained a strong financial position with $53.2 million in cash and investments and no outstanding debt.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.